Auna S.A. reported a 3% decline in revenues for the fourth quarter of 2025, primarily due to soft market conditions in Mexico affecting surgeries and emergency visits. Despite flat revenues compared to the previous quarter, the company noted signs of stabilization and expects to sustain top-line and EBITDA growth in 2026. In contrast, oncology revenues rose by 35% sequentially, partly due to the integration of Opcion Oncologia and a new Oncocenter launch at Doctors Hospital.
In December, 12% of total revenues in Mexico came from the Out-of-Pocket segment, showing an 8% increase from Q3. Auna has implemented strategic actions aimed at expanding its reach among privately insured families and established favorable relationships with major insurers to drive volumes across key services. Approximately 250 physicians involved in the hospital network confirmed improvements in both volume and margins, contributing to stronger overall performance.
In share performance, Auna’s stock has increased by 14.1% over the past three months, outperforming the industry average drop of 7.6%.
